Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HairDX, a subsidiary of PharmaGenoma and a molecular dermatology R&D company, has introduced The HairDX genetic test for finasteride, a genetic test for predicting finasteride response for the treatment of common hair loss.
Subscribe to our email newsletter
According to the company, The HairDX (RxR) genetic test for finasteride response will help doctors predetermine if patients will have a subtle, moderate, or great treatment response to finasteride, allowing the physician to provide patients with the best treatment regimen to save their hair.
Finasteride works by blocking the production of the androgen called dihydrotestosterone, the hormone responsible for hair loss in androgenetic alopecia (AGA).
The androgen receptor gene has been identified as a major determinant of AGA, commonly called male pattern baldness. Certain variants of the nucleoside sequence on the androgen receptor gene, known as CAG repeats, appear to determine androgen sensitivity in men. The HairDX (RxR) genetic test for finasteride response provides doctors with a patient score, called the CAG repeat score, the company said.
Sharon Keene, chief medical officer of HairDX, said: “A smaller CAG test score is associated with an increased response to finasteride for treatment of AGA. Scientists discovered that among men that had the best response to finasteride approximately 70% had a CAG score below 22 while among men that had a subtle response to finasteride approximately 70% had a CAG score above 22.”